跳至主要内容
临床试验/NCT05893498
NCT05893498进行中(未招募)不适用

Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment

CathWorks Ltd.59 个研究点 分布在 4 个国家目标入组 1,924 人开始时间: 2023年6月21日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
1,924
试验地点
59
主要终点
MACE

研究概览

简要总结

To test whether FFRangio-guided treatment is non-inferior to conventional pressure wire-guided treatment in patients with coronary artery disease.

详细描述

ALL-RISE is a prospective, randomized, multi-center, controlled post-market study. The ALL-RISE study is designed to test whether FFRangio-guided treatment is non-inferior to conventional pressure wire-guided treatment in patients with coronary artery disease being evaluated for percutaneous coronary intervention (PCI) with respect to major adverse cardiac events (MACE) at one year.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 1. Adult patients (≥18 years of age) with one or more study lesion(s) (diameter stenosis 50-90%) deemed appropriate for both pressure-wire and FFRangio physiologic assessment.

排除标准

  • Subject with ST-elevation (MI (STEMI) within 72 hours at time of study enrollment
  • Prior coronary artery bypass graft (CABG) with patent grafts to the study vessel(s)
  • Patients undergoing coronary physiologic assessment where one possible outcome is referral for CABG
  • The study vessel supplies a significant nonviable territory (e.g., prior transmural MI)
  • Severe left sided valvular heart disease
  • Most recent documented LVEF ≤30%
  • Women who are pregnant or breastfeeding (women of childbearing potential are required to have negative pregnancy test within 1 week of index procedure)
  • Patients with life expectancy <1 year life as estimated by treating physician.
  • Subjects enrolled in other ongoing non-registry clinical studies that would impact conduct or outcomes of this study (registries and long-term follow-up of other studies are allowed)
  • Subjects who have undergone angiographic or wire-based coronary physiological assessment for 1 or more potential study lesions within 30 days of enrollment.
  • Angiographic Exclusion Criteria:
  • Coronary angiogram is not acquired per instructions as defined in the Study Protocol
  • Sthe study lesion is the clear culprit for a NSTEACS
  • Angiographic evidence of a procedural complication (e.g., acute stent thrombosis, flow-limiting dissection, perforation, slow/no reflow, or other) prior to randomization
  • Thrombolysis in myocardial infarction (TIMI) Grade 2 flow or lower in any study vessel at time of enrollment
  • The study vessel is in a left coronary vessel with separate left anterior descending and left circumflex ostia arising from the aorta
  • The study lesion involves the left main coronary artery (stenosis ≥ 50%)
  • The study lesion is in an ectatic or aneurysmal coronary segment (defined as lumen diameter 1.5x diameter or the reference vessel)

研究组 & 干预措施

FFRangio

Experimental

FFRangio guided revascularization

干预措施: FFRangio (Device)

Pressure wire

Active Comparator

Pressure wire-based guided revascularization (FFR or NHPR)

干预措施: FFR or NHPR (Device)

结局指标

主要结局

MACE

时间窗: 1 year

Rate of the composite of all-cause death, myocardial infarction (MI) or unplanned clinically-driven revascularization

次要结局

  • Patient Reported Quality of Life - EQ-5D(Baseline, Day 30 and 12 Months)
  • Procedure Time(24 hours)
  • Stroke(30 Days)
  • FFRangio Usability(24 hours)
  • All-Cause Mortality(12 months)
  • Unplanned Revascularization(12 months)
  • Peri-Procedural Complications(30 Days)
  • Bleeding(30 Days)
  • Patient Reported Health Status - SAQ-7(Baseline, Day 30 and 12 Months)
  • Contrast Dose(24 hours)
  • Cost-effectiveness(12 Months)
  • Myocardial Infarction(12 months)
  • Kidney Injury(30 Days)
  • Radiation Dose(24 hours)
  • Resource utilization(24 hours)
  • Stent thrombosis(12 months)
  • Pressure Wire Usability(24 hours)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (59)

Loading locations...

相似试验